Medical/Pharmaceuticals
Workforce shortages and limited public hospital capacity remain major barriers to stroke care in the Philippines, new report finds
Filipino experts call for equipping more public hospitals with advanced imaging technology, stronger EMS infrastructure and greater investment in specialist training to close these gaps MANILA, Philippines, Sept. 2, 2026 /PRNewswire/ -- Workforce shortages and limited public hospital capacity re...
2026-09-02 15:00
5340
Delays before patients reach stroke centres remain a major barrier to timely treatment in Malaysia, new report finds
Malaysia experts call for better public awareness of stroke symptoms, standardised hospital imaging protocols and expanded access to specialist care beyond major urban centres KUALA LUMPUR, Malaysia, Sept. 2, 2026 /PRNewswire/ -- Delays occurring before patients reach stroke centres remain a maj...
2026-09-02 15:00
5808
Delays Before Patients Reach Stroke Centers Still Hinder Timely Treatment Across Southeast Asia, Siemens Healthineers Report Finds
New research commissioned by Siemens Healthineers shows transportation delays, slow reporting processes as leading barriers to timely stroke diagnosis. * Stronger referral networks, public awareness, AI-enabled diagnostics, coordinated care are key to strengthening stroke system readiness acros...
2026-09-02 15:00
5389
"From Canine Fat Tissue to Insulin-Producing Cells": Chula Veterinary Researchers Offer New Hope for Diabetes Treatment in Pets
While diabetes is commonly associated with humans, the disease also affects dogs and cats. Its impact on the quality of life of both pets and their owners is often greater than many people realize. BANGKOK, Sept. 2, 2026 /PRNewswire/ -- In dogs, diabetes is similar to Type 1 diabetes in humans, ...
2026-09-02 14:23
3542
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
* The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. * Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement an...
2026-09-02 09:27
2487
Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
Haier Biomedical Accelerates Its Transformation into an Intelligent
Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026
SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Haier Biomedical
2026-09-01 22:50
3703
Super MOXI® by Sciton Ushers in a New Era of Head-to-Toe Skin Revitalization
PALO ALTO, Calif., Sept. 1, 2026 /PRNewswire/ -- Sciton Inc., a pioneer and leader in medical and aesthetic laser and light-based technologies, today announced the launch of Super MOXI® with High Density (HD) Delivery™, a major evolution of its award-winning MOXI® laser that brings new speed, ver...
2026-09-01 21:10
3144
Suki Named a Transformational Innovation Leader in Ambient Clinical Intelligence by Frost & Sullivan
2026 recognition highlights Suki's innovation, clinical quality and measurable
impact as Ambient Clinical Intelligence expands across the enterprise
SAN ANTONIO, Sept. 1, 2026 /PRNewswire/ -- Suki
2026-09-01 21:00
2144
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Pa...
2026-09-01 19:30
2404
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib Plus Fulvestrant, With Palbociclib, Versus Standard-of-Care First Patient Expec...
2026-09-01 19:15
2645
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
ROCKVILLE, Md., Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel. Dr. Chen brings nearly two decades of lega...
2026-09-01 19:00
2847
JIANGXI BIO Announced 2026 Interim Results
Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody Interim Results Highlights Key Financial Indicators * Revenue amounted to RMB83.3 mn; gross profit amounted to RMB60.3 mn, ...
2026-09-01 14:44
6712
Siemens Healthineers showcases its AI-powered technological innovations to redefine healthcare delivery in Southeast Asia
* Spotlights how scaling AI and big data can make clinical pathways more efficient * Hosts its second ASEAN CEO Summit to drive collaboration amongst healthcare leaders to redefine care delivery in Southeast Asia * Unveils new regional report "Strengthening Stroke System Readiness Across AS...
2026-09-01 11:00
4386
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET
SYDNEY, Sept. 1, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-09-01 07:23
5454
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning 1 September 2026 LAVAL, QC, Sept. 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics busines...
2026-09-01 06:00
2977
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-31 20:38
5365
Fosun International Holds 2026 Interim Results Presentation: Unlocking Core Pathways, Accelerating Growth in Industries where we Excel
HONG KONG, Aug. 31, 2026 /PRNewswire/ -- On the morning of 28 August, Fosun International held its 2026 interim results presentation in Hong Kong. This marks Fosun's return to Hong Kong to hold a results presentation for the first time in six years. The results presentation was attended by Guo Gu...
2026-08-31 17:43
4607
SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with...
2026-08-31 12:17
1777
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
* Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at lea...
2026-08-31 09:00
2719
Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research
Data4Life and Monash Health have partnered to optimize clinical trial design
and execution, complemented by educational workshops and professional training
programs, with a shared commitment to improving patient outcomes.
- Picture is available at AP
2026-08-31 07:00
1857
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52348
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51309
